🔴 WE HAVE SOMETHING TO CELEBRATE: OUR FIRST FULL ISSUE
@NatureCancer
IS LIVE ‼️ - GIVE US BIGGER CAPS TO SHOW OUR EXCITEMENT!! 🥳 🥳 Massive congrats to the team, and thanks to everyone that made this a reality. Stay tuned for our content:
Hello twitterverse!
#NatureCancer
, the new journal in the
@nature
family, is here. Our mission is to embrace the breadth of
#CancerResearch
from basic preclinical to translational and clinical work across the natural, applied and social sciences
NEW CONTENT
@NatureCancer
'A protein expression atlas on tissue samples and cell lines from cancer patients provides insights into tumor heterogeneity and dependencies' by Akbani, Mills, Liang and collaborators
🔥🔥 ONLINE NOW
@NatureCancer
: "The interaction of CD4+ helper T cells with dendritic cells shapes the tumor microenvironment and immune checkpoint blockade response", by
@IdoAmitLab
@MiriamMerad
#AmosTanay
& Co
Find it here!
⚡️ONLINE NOW
@NatureCancer
: "Moving pan-cancer studies from basic research toward the clinic" - a fantastic Review by Li Ding & Co
@WUSTLmed
Don't miss it! 👇👇
⭐️ONLINE NOW
@NatureCancer
: "Multi-omic profiling of peritoneal metastases in
#GastricCancer
identifies molecular subtypes and therapeutic vulnerabilities" by Tanaka, Mano, Yatabe &Co
Don't miss it! 👇
#Metastasis
#Therapy
⚡️The "Milestones in Cancer" is out and is WONDERFUL. It covers key developments across cancer research in the last 20 years - coordinated by
@SafiaDanovi
and
@SaheliSadanand
with input from all cancer editors
@NatResCancer
The interactive timeline is🤩
⚡️Check out this beautiful paper
@NatureCancer
: Pan-cancer analysis of advanced/metastatic post-therapy patients reveals interactions between therapy and genomic landscapes, a new cohort by
@mmarra0630
and co.
Read it now:
🔥🔥 ONLINE
@NatureCancer
: 2 studies from
@yibinkang
&Co discover MTDH-SND1 inhibitors for metast
#BreastCancer
therapy via cell- and non-cell-autonomous effects
DON'T MISS THEM! 👇
💫ONLINE NOW
@NatureCancer
– the
#2023Generation
– 12 group leaders share their journey to becoming an independent PI. Very inspiring stories, please do not miss them!
⚡️Check our Issue2 Editorial
@NatureCancer
focused on AI in cancer
⚡️We also have a fantastic
#Viewpoint
in which we gathered six scientists to discuss challenges, hopes and hypes of
#AI
in cancer research, diagnosis and care.
🔥 ONLINE NOW
@NatureCancer
: "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide
#PrecisionOncology
" - a tour de force paper by
@VanAllenLab
&Co
Don't miss it! 👇👇
Happy International Women's Day
#IWD2023
!
@NatureCancer
supports
#WomenInScience
- please join us to celebrate some of the wonderful female scientists & clinicians who recently published their work with us – we hope you are inspired by them! 👩🔬
12 early-career investigators across the globe 🌍 reflect on the challenges faced by their scientific communities in 2021 and highlight emerging opportunities.
#2021InReview
Read it👇
New content 🌟Perspective🌟
"Targeting therapy-persistent residual disease"
by Xiaoxiao Sun, Lani Wu, Steven Altschuler & Aaron Hata
@ucsfpharmacy
@MGHCancerCenter
🔗
✨
@NatureCancer
starts 2023 with exciting new studies – “Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer” by
@RonDePinho
& Co.
👇
🔴 Our second publication
@NatureCancer
is online! Led by
@nlbigas
and Abel Gonzalez-Perez - Systematic analysis of alterations in the ubiquitin proteolysis system reveals its contribution to driver mutations in cancer
@IRBBarcelona
Read it here:
✨In our
#2023InReview
special we provide a collection of 12 research highlights summarizing impactful papers published in 2023 and present a collection of some of our most striking
@NatureCancer
publications.
Check them out for some end-of-year reading.
⭐️ONLINE NOW⭐️
@NatureCancer
“A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology” by
@AlanaWelm
@BryanWelm
&Co.
Read it here:
Check out new content
@NatureCancer
"A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistance"
by Judith Sebolt-Leopold's lab
💫NEW CONTENT
@NatureCancer
“The immunopeptidome landscape associated with T cell infiltration, inflammation and immune editing in lung cancer” by
@michal_bassani
& Co.
Don't miss it👇
As part of our focus issue for
#2021InReview
Caroline Robert
@GustaveRoussy
provides a clinical outlook on checkpoint inhibition directed against LAG-3.
Read it here 👇
🔴Our 3rd publication
@NatureCancer
is out! Ribas and co. show that PAK4 inhibition improves anti-PD-1
#cancer
#immunotherapy
by reducing Wnt activation and increasing TILs
@UCLA
@Parkerici
Read here ->
Stay tuned to our full launch in January!! 🥳 🥳
⭐️ONLINE NOW
@NatureCancer
: A novel CD25 mAb depleting Tregs & preserving IL2 signaling in T effector cells enhances anti-tumor
#immunity
- by
@QuezadaLab
& Co. And a follow up trial launched already!
Read it here:
#Immunotherapy
🔴We are looking for an Associate or Senior Editor to join the
#editorial
team
@NatureCancer
If you are passionate about
#science
and have a PhD in
#cancer
research or a related field, have a look at the link below and feel free to reach out to us.
⭐️NEW CONTENT
@NatureCancer
“Modeling T cell temporal response to cancer immunotherapy rationalizes development of combinatorial treatment protocols”
#immunotherapy
⚡️ONLINE NOW
@NatureCancer
: "Few-shot learning creates predictive models of drug response that translate from high-throughput screens to individual patients" by
@TreyIdeker
Don't miss it!
🔥ONLINE NOW
@NatureCancer
– “EZH2 inhibition remodels the inflammatory senescence-associated secretory phenotype to potentiate pancreatic cancer immune surveillance” by
@LoweLabMSKCC
@Marcus_Ruscetti
& Co.
👇Read it here
✨NEW CONTENT
@NatureCancer
– “Fucosylation of HLA-DRB1 regulates CD4+ T cell-mediated anti-melanoma immunity and enhances immunotherapy efficacy” by
@EricLauLab
& Co.
Read it here👇
Online Now - Resource
"Spatial single-cell protein landscape reveals vimentinhigh macrophages as immune-suppressive in the microenvironment of hepatocellular carcinoma"
by Hongyang Wang & Lei Chen and team
🔔NEW RESEARCH CONTENT
@NatureCancer
on 'Tumor-associated macrophages restrict CD8+ T cell function through collagen deposition and metabolic reprogramming of the breast cancer microenvironment'
Check it out here:
🤩Two
#epigenetic
#therapy
papers for AML
@NatureCancer
ONLINE JUST NOW!
🔥Here is a NVs by Uli Steidl discussing implications, challenges and next steps in this important topic:
🔬 Three reports today
@nature
show that tumor cells can engage in synaptic connections with neurons, and this reciprocal interaction impacts the way brain tumors progress
#NatureCancerPicks
#thread
👇👇👇